Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

February 26, 2025 at 08:17 AM EST

AMPH Cover Image

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect.

Amphastar Pharmaceuticals missed analysts’ revenue expectations by 1% last quarter, reporting revenues of $191.2 million, up 5.9% year on year. It was a softer quarter for the company, with a miss of analysts’ EPS estimates.

Is Amphastar Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Amphastar Pharmaceuticals’s revenue to grow 6.2% year on year to $189.2 million, slowing from the 31.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.94 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amphastar Pharmaceuticals has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Amphastar Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Supernus Pharmaceuticals delivered year-on-year revenue growth of 6%, beating analysts’ expectations by 12.2%, and Jazz Pharmaceuticals reported revenues up 7.5%, topping estimates by 2.8%.

Read our full analysis of Supernus Pharmaceuticals’s results here and Jazz Pharmaceuticals’s results here.

Stocks, especially growth stocks where cash flows further in the future are more important to the story, had a good 2024. An economic soft landing (so far), the start of the Fed's rate cutting campaign, and the election of Donald Trump were positives for the market, and while some of the pharmaceuticals stocks have shown solid performance, the group has generally underperformed, with share prices down 4.4% on average over the last month. Amphastar Pharmaceuticals is down 12.5% during the same time and is heading into earnings with an average analyst price target of $44.40 (compared to the current share price of $32.38).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

About Us

Additional Information

Website & Technical Help

Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow

More News